ALT-803, an IL-15 superagonist, in combination with nivolumab in ...
ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 μg/kg. The primary endpoint was to define safety and tolerability and to establish a recommended …
IL-15靶向药：新生代抗癌之光? - 知乎 - 知乎专栏
19年SABCS会议上，三联疗法（采用“三角进攻”策略使用超级激动剂N-803、PD-L1抑制剂Avelumab和靶向CD16的haNK）首次大放光彩。 在转移性三阴性乳腺癌（TNBC）的临床试 …
抗癌神药ALT-803免疫联合治疗疾病控制率达100%！ - 知乎
为了克服白介素-15这个弱点，同时提高药物生产效率，美国AltorBioScience公司开发了一种白介素-15强力激动剂ALT-803，它不但功能和白介素-15一样，且体内 半衰期长达25小时。 临床 …
ALT-803（IL-15 超级激动剂）与抗体的新型融合显示出抗原特异性 …
The IL-15N72D/IL-15RalphaSuFc complex, also known as ALT-803, is a multimeric complex constructed by fusing IL-15N72D/IL-15RalphaSu to the Fc-domain of IgG1. ALT-803 is an IL …
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in …
2018年11月15日 · Given the superior activity and favorable kinetics of ALT-803 (IL15N72D:IL15RαSu/IgG1 Fc complex) over recombinant human IL15 (rhIL15) in animal …
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with …
ALT-803 is an IL-15 superagonist complex that has been developed as a potent antitumor immunotherapeutic agent and is in clinical trials. Here we describe the creation of a novel …
Comparison of the super agonist complex, ALT-803, to IL-15 as …
ALT-803 is a complex of an IL-15 superagonist mutant and a dimeric IL-15 receptor αSu/Fc fusion protein that was found to exhibit enhanced biologic activity in vivo with a substantially longer …
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent …
ALT-803 is an interleukin-15 superagonist complex that enhances ADCC against human carcinoma cells in vitro and exerts an antitumor activity in murine, rat, and human carcinomas …
PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT …
Given the superior activity and favorable kinetics of ALT-803 (IL-15N72D:IL-15RαSu/IgG1 Fc complex) over recombinant human IL-15 (rhIL-15) in animal models, we performed this first-in …
ALT-803 in the treatment of non-muscle-invasive bladder cancer ...
2022年11月9日 · ALT-803 (N-803) is an IL-15 superagonist and reduces tumor burden by promoting the proliferation and activation of NK cells and CD8 + T cells. The FDA received (23 …